Rapid Micro Biosystems, Inc. · NASDAQ:RPID
Rapid Micro Biosystems — Sidoti Small-Cap Conference (September 2026)
19 slides from Rapid Micro Biosystems's conference presentation, Sep 24, 2026
Slide 1: Sidoti Small-Cap Conference
Sidoti Small-Cap Conference September 24, 2026 RAPID MICRO BIOSYSTEMS NASDAQ: RPID © 2026, Rapid MicroMicro Rapid Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered Biosystems trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Bio
Slide 2: Disclaimers
Disclaimers This presentation has been prepared by Rapid Micro Biosystems, Inc. (the “Company”) solely for informational purposes. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exch
Slide 3: The standard in automating microbial quality control
2025 REVENUE G L O B A L S Y S T E M S (1) CUSTOMERS $34M 200 75% Total Revenue Cumulative Placements Top 20 Global Pharma (2) The standard 20% 169 86% in automating Year / Year Growth Cumulative Validations Approved CAR-T Manufacturers microbial quality control $18M ~20 Recurring Revenue Countries
Slide 4: Strategically well positioned for growth and margin expansion
Strategically well positioned for growth and margin expansion • Strong business fundamentals with 200 systems placed globally and >50% recurring revenue • Expanding enterprise deployments and multi-system opportunities with leading global biopharma customers • Recurring revenue powered by increasing
Slide 5: Our vision
We are transforming a critical, Our regulated part of the global pharmaceutical manufacturing C vision process, bringing microbial quality control into the 21st century. The new standard in microbial quality control Rapid Micro Biosystems © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS
Slide 6: Microbial quality control has not kept up with pharma industry innovation
Microbial quality control (MQC) has not kept up with pharma industry innovation F AC TO RS D R I V I N G CH AN G E Scientific and Growing demand for Faster & leaner Data integrity & Regulatory + + + + technology innovation more complex therapies manufacturing security focus scrutiny TODAY TODAY TODA
Slide 7: Challenges in a traditional MQC lab
Challenges in a traditional MQC lab High volume testing mandated by regulators Insecure and lacking data integrity Subjective and prone to human error Manual, paper-based and slow Rapid Micro Biosystems © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered
Slide 8: Modernizing MQC with the Growth Direct platform
Modernizing MQC with the Growth Direct® platform The only fully automated, high-throughput and secure MQC solution… …designed to deliver a compelling value proposition Data Supports global quality regulatory compliance Proprietary Integrity and improved data handling and management Consumables Enabl
Slide 9: Growth Direct automates all MQC tests in pharma manufacturing
Growth Direct® automates all MQC tests in pharma manufacturing For Environmental Monitoring • Tryptic Soy Agar (TSA) with Lecithin • TSA with LP80HT (histidine and thiosulphate) For Water Testing • R2 Agar (R2A) The only fully automated non-destructive growth- based technology impacting For Bioburde
Slide 10: Growth Direct modernizes MQC
Growth Direct® modernizes MQC MANUAL WORKFLOW 1. 2. 3. 4. 5. 6. 7. 8. Manual & subject to error PULL QC FILL OUT PREPARE LOAD PULL PERFORM RECORD R ETUR N TEST FORM AS SAY IN FO SA MP LE S INC UBATOR SA MP LE S C OU NTS C OU NTS SA MP LE S 15 steps 9. 10. 11. 12. 13. 14. 15. 5-14 days to result / te
Slide 11: The Growth Direct System brings MQC into the 21st Century
The Growth Direct® System brings MQC into the 21st Century F AC TO RS D R I V I N G CH AN G E Scientific and Growing demand for Faster & leaner Data integrity & Regulatory + + + + technology innovation more complex therapies manufacturing security focus scrutiny TODAY QC & Analysis TODAY TODAY Disco
Slide 12: Market forces pushing pharma industry to automation
Market forces pushing pharma industry to automation Expanding Large and Regulatory Industry Manufacturing Growing Market Pressure Change Capacity, Especially $5B annual recurring Increasing regulatory Growth in complex U.S. Reshoring revenue + $5B global scrutiny and biologics and cell & system oppo
Slide 13: Land and expand growth strategy augmented by innovation
Land and expand growth strategy augmented by innovation GROW NEW DRIVE ENTERPRISE EXPAND INTO LAUNCH NEW PURSUE ADJACENT CUSTOMER ADOPTION DEPLOYMENTS NEW GEOGRAPHIES PRODUCTS MARKETS AND SERVICES BIO PHARMA + Sample (incl. cell Site automation & gene) 1 EM + W/BB + Sterility Additional test types (
Slide 14: Customer base includes 75% of the top 20 global pharma companies
Customer base includes 75% of the top 20 global pharma companies1 with significant growth potential C U S T OME R S E G ME N T S WIT H E S T AB L ISH ED U S E G L O B AL S IT E S WIT H GR OWT H D IR E CT SYS T E MS Biologics Cell & Gene Therapy / CAR-T CDMO Personal Care Products Small Molecules 200
Slide 15: Distribution & Collaboration Partnership with Merck KGaA (MilliporeSigma)
Distribution & Collaboration Partnership with Merck KGaA1 (MilliporeSigma) P a r tn er sh ip Hi g h l ig h t s • Global, 5-year, co-exclusive right to sell Growth Direct systems & consumables • Minimum commitment for Growth Direct system purchases in each of the first two years • Leverage MilliporeS
Slide 16: Delivering consistent 20%+ revenue growth
Delivering consistent 20%+ revenue growth REVENUE Potential Revenue Growth Drivers Recurring • Scale existing Top 20 pharma customers Non-recurring through site and application expansion • Win new Top 20 and core pharma $37 - $41M (1) customers • Expand new products / services $17M • Meaningful Mill
Slide 17: Significant progress and clear path to potential 50%+ gross margin
Significant progress and clear path to potential 50%+ gross margin GROSS MARGIN % 50% 50%+ (exit) 56 percentage point ~20% improvement (actual) 6% (1) 0% Contribution to overall Expected primary drivers of 2026 Improvement improvement • Systems: Material cost reduction, volume leverage (50%) • Consu
Slide 18: Creating the future of rapid, secure MQC automation
Creating the future of rapid, secure MQC automation to drive sustainable, long-term growth and shareholder value Growth Direct® is the industry-leading platform Chosen by 75% of the top 20 global pharma Operating behind companies(1) with significant Enabling advanced strong barriers to entry commerc
Slide 19: Thank you
Thank you © 2026, Rapid MicroMicro Rapid Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered Biosystems trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems — Sidoti Small-Cap Conference (September 2026) on 6ix